Shionogi's $2 Billion IntraBio Buyout Heads $2.3 Billion October M&A

Shionogi paid $2 billion for Texas-based IntraBio in October 2026, the priciest biotech acquisition of a month in which licensing deals spanned small molecules, antibodies, proteins and AI platforms. Four M&A transactions dominated headlines, while Roche alone signed three partnership deals in the month.

IntraBio brings the FDA-approved small molecule Aqneursa for Niemann-Pick disease type C and ataxia, both neurological conditions. The EU greenlit the drug for both diseases this year. Osaka-based Shionogi, which specializes in infectious diseases and antimicrobial resistance, will use the acquisition to enter rare diseases.

What did the other acquirers pay?

Viatris, headquartered in Pennsylvania, bought California pain-management company Pacira BioSciences for $1.65 billion. The deal hands Viatris the FDA-approved non-opioid injectable Zilretta for knee osteoarthritis pain, the post-surgical analgesic Exparel, and Pacira's preclinical and clinical pipeline.

German Merck plans to secure London-based Silence Therapeutics for $1.3 billion. Silence's lead candidate, divesiran, is a phase 3-ready siRNA gene-silencing therapy for polycythemia vera, a rare blood cancer in which bone marrow overproduces red blood cells.

Gilead paid a $1.275 billion upfront for Shanghai-based PepStar Therapeutics, which holds an oral inflammation drug program. The purchase follows Gilead's June buyout of Ouro Medicines and deepens its immunology push.

How did small molecules and degraders fare?

Menarini Group tapped Maryland-based Georgiamune for GIM-621, an oral small molecule immunotherapy for solid tumors now in preclinical trials. Menarini pays $45 million upfront and near-term within a total deal value of up to $1.1 billion for worldwide rights.

Pfizer partnered with Paris-based Enodia Therapeutics in a $500 million agreement to discover and develop Sec61 inhibitors using Enodia's Sec61 Translocon modulation platform, an approach that inhibits disease-causing proteins.

Ono Pharma took over development and commercialization of Biohaven's IgG degrader BHV-1300, now in phase 3 studies for Graves' disease. The Connecticut biotech receives up to $100 million in near-term payments, including $80 million upfront, plus $20 million in potential milestones.

Which antibody deals carried the biggest numbers?

Sanofi's collaboration with Regeneron carries the largest headline value. Regeneron gains $1 billion upfront and up to $7 billion in milestones to co-develop four long-acting antibodies it has already discovered, including the IL-13-targeted REGN20423.

CSL and Alentis Therapeutics will co-develop lixudebart, an anti-claudin-1 monoclonal antibody for rare kidney and liver diseases; claudin-1 is implicated in fibrosis. Alentis can score $355 million upfront and up to $1.2 billion in milestones.

Why are T-cell engagers climbing the licensing ladder?

Roche teamed with Vancouver-based Zymeworks on ZW209, a trispecific T-cell engager targeting DLL3 on tumor cells while binding CD3 and CD28 to prevent unintended T-cell activation. Zymeworks bags $55 million upfront, $40 million when the phase 1b trial begins, and up to $718 million in milestones; the drug is now in phase 1a.

Gilead is spending up to $135 million on Vir Biotechnology to engineer three PRO-XTEN dual-masked T-cell engager candidates, using Vir's technology to shield the molecules in circulation.

Novartis took command of Abogen's ABO2203, the first mRNA-encoded T-cell engager to reach the clinic for autoimmune diseases, plus other programs from the Jiangsu company's RNA platform. Abogen rakes in $575 million upfront and up to $7.2 billion in milestones.

How large did the ADC deals run?

Roche's pact with Shanghai-based Hansoh Pharma is October's richest licensing agreement: $400 million upfront, a $110 million first-anniversary payment, and more than $15 billion in milestones. It covers two of Hansoh's preclinical ADCs plus multiple candidates built on Hansoh's platform around Roche-discovered targets. Roche holds global rights except China, Hong Kong, Macau and Taiwan, where Hansoh retains development and commercialization. The Swiss pharma also signed a September deal with bispecific developer Simcere Zaiming.

AstraZeneca and Daiichi Sankyo, which own the ADC Datroway — FDA-approved for triple-negative breast cancer in April — cut an undisclosed-terms deal with Summit Therapeutics to evaluate Datroway in combination with Summit's ivonescimab. Summit licenses ivonescimab from Akeso outside China, where Akeso holds rights.

What drew big pharma to proteins and RNA?

Zealand Pharma and Generate Biomedicines will develop AI-engineered protein therapies for metabolic diseases. Generate nabs $30 million upfront, up to $35 million in early preclinical milestones, and up to nearly $1.2 billion in total milestones.

Astellas struck two protein pacts: one with AI Proteins, worth more than $400 million in upfront and milestone payments for miniprotein discovery, with Astellas handling development and commercialization; and one with Australia's Audax Biosciences, valued at up to $1.34 billion, for DAX-044, a phase 1 IL-12 antibody-cytokine fusion for solid tumors, with Audax retaining an option to co-fund in Australia and New Zealand.

Genentech paid Alector $100 million upfront with up to $1.17 billion in milestones for AL050, a preclinical enzyme replacement therapy addressing GCase deficiency driven by GBA1 mutations, a mechanism linked to Parkinson's disease.

In RNA, Sanofi licensed candidates to be modified with ScionxBio's TERA platform, which extends how long RNA molecules persist in the body; terms were not disclosed and ScionxBio leads work through in vivo validation. Roche wants Rona Therapeutics' siRNA against ALK7, highly expressed in adipose tissue in obesity; blocking the enzyme reduces fat while preserving lean mass. Rona earns up to $100 million upfront and near-term, plus up to $1.06 billion in milestones.

Where does AI fit in?

AstraZeneca pays insitro $40 million upfront and up to $1.46 billion in milestones to apply its Virtual Human AI platform to new targets in MASH and cardiomyopathies. GSK secured access to Chai Discovery's protein folding and design models, with wet-lab testing at GSK to vet candidates; terms undisclosed. Lilly will develop lipid nanoparticles from Hong Kong-based METiS TechBio's AI platform, with METiS eligible for up to $1.1 billion in milestones.

October's pattern is unambiguous: acquirers concentrated on approved or late-stage assets, while licensors pushed headline values past $15 billion on milestone-heavy structures that shift development risk to sellers.